DBCG trial 89B comparing adjuvant CMF and ovarian ablation: Similar outcome for eligible but non-enrolled and randomized breast cancer patients

By Ejlertsen Bent   Jensen Maj-Britt   Mouridsen Henning   Andersen Jørn   Cold Søren   Jakobsen Erik   Kamby Claus   Sørensen Peter   Ewertz Marianne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 709-717

Informa Healthcare

Access to resources Recommend Favorite

PI-PLCβ1 gene copy number alterations in breast cancer

By              

Oncology Reports, Vol. 27, Iss. 2, 2012-01 ,pp. : 403-408

Spandidos Publications

Access to resources Recommend Favorite

Recurrence pattern and prognosis in low-risk breast cancer patients - Data from the DBCG 89-A programme

By Christiansen Peer   Al-Suliman Nidal   Bjerre Karsten   Møller Susanne  

Acta Oncologica, Vol. 47, Iss. 4, 2008-01 ,pp. : 691-703

Informa Healthcare

Access to resources Recommend Favorite

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D

By Gunnarsdóttir Katrín  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 163-169

Springer Publishing Company

Access to resources Recommend Favorite

Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer

By Yom Cha  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 647-655

Springer Publishing Company

Access to resources Recommend Favorite